Indications
- reduces the risk of acute cardiac ischemic events (death and/or
myocardial infarction)
- in patients with unstable angina or
non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction
(i.e., non-ST-segment elevation acute coronary syndromes)
Administration/AbsorptionDosage
DistributionMechanismExcretionSide effectsInteractions
Contraindications
- Thrombocytopenia :
The drug is contraindicated in patients with platelet counts of less
than 100,000 per μl because no clinical experience exists regarding
such patients.
- Renal insufficiency :
Eptifibatide undergoes renal elimination. In such patients with renal
insufficiency where a glycoprotein IIb/IIIa inhibitor is likely to
provide benefit, Abciximab (trade name: Reopro) is an alternative medication.
- Current bleeding tendencies or abnormally prolonged coagulation
parameters observed within 30 days before starting therapy with
eptifibatide is intended.
- Coagulation parameters such as ACT, aPTT, TT, and PT should be followed closely during therapy and afterwards.
- Allergy to eptifibatide and/or other ingredients.
- Severe, uncontrolled hypertension.
- Pregnancy : No experience exists. Pregnant patients should be treated only when clearly needed.
- Lactation : No human data exists. Breast-feeding should be avoided during treatment in order to prevent damage to the newborn.
- Geriatric patients : No differences in side effects compared with
younger patients have been seen. Nevertheless, geriatric patients
should be very closely observed for bleeding and other side-effects.
- Pediatric patients : Eptifibatide is not indicated in patients below 18 years of age, because no experience exists.
|
|
